Physician profile
John Ellena
NPI 1487767240
$10,471.36
in general payments reported to CMS, 2019-2025
64 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,557 · 2020: $1,667 · 2021: $1,946 · 2022: $1,534 · 2023: $1,597 · 2024: $1,866 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,717 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,717.20 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,823.58 | 2019-2025 | |
| Pfizer INC. | $693.75 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $687.92 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $641.93 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $634.49 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $611.67 | 2019-2025 | Jardiance, Tradjenta |
| Lilly USA, LLC | $479.04 | 2019-2024 | Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $416.06 | 2019-2024 | Xarelto |
| Amgen INC. | $391.78 | 2019-2024 | Repatha, Otezla, Prolia |
| Novartis Pharmaceuticals Corporation | $292.31 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $283.90 | 2022-2024 | Nuplazid |
| Allergan, INC. | $256.53 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $209.03 | 2019-2025 | Eliquis |
| Merck Sharp & Dohme LLC | $207.40 | 2020-2023 | Belsomra, Steglatro |
| Abbott Laboratories | $203.14 | 2020-2024 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ellena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.